GxP is the collective term for the regulated “Good x Practice” frameworks in the pharmaceutical sector. The “x” stands for the respective area of activity, such as manufacturing, clinical trial, non-clinical trial, distribution or pharmacovigilance. Together, these frameworks require traceable, risk-appropriate processes to protect individuals, ensure product quality and guarantee the reliability of regulated data.
GxP as a family of regulations
GMP, Good Manufacturing Practice, encompasses the principles and guidelines for manufacturing and quality control of medicinal products and investigational medicinal products. In the European Union, EudraLex Volume 4 bundles these GMP guidelines; for investigational medicinal products, Delegated Regulation (EU) 2017/1569 supplements Regulation (EU) No 536/2014. ICH Q7 specifies GMP principles for active substances, while ICH Q10 describes a model for the pharmaceutical quality system.
GCP, Good Clinical Practice, is the ethical, scientific and quality standard for clinical trials with human participants. ICH E6(R3) combines the protection of rights, safety and well-being with reliable results. Regulation (EU) No 536/2014 requires clinical trials to be conducted according to the principles of good clinical practice. GCP includes, among other things, the protocol, informed consent, data, roles, monitoring and documentation.
The most important GxP areas
GLP, Good Laboratory Practice, concerns non-clinical safety studies, for which the principles of good laboratory practice are decisive in the EU. It ensures the planned execution and traceable documentation of such studies. GDP, Good Distribution Practice, regulates the appropriate storage and distribution of medicinal products and, in separate guidelines, of active substances. The aim is to maintain quality and traceability in the supply chain.
GVP, Good Pharmacovigilance Practices, designates the requirements for the monitoring and evaluation of drug safety post-authorization. They structure processes for the collection, evaluation and reporting of safety information, for example. Depending on the activity, further GxP-related requirements may be relevant. The collective term, however, does not replace checking which specific regulations apply in individual cases.
Despite different areas of application, GxP frameworks follow recurring principles: clear responsibilities, qualified personnel, controlled documentation, integrity of data and records, risk-appropriate controls as well as the oversight of outsourced activities. A quality management system bundles these elements within an organization. ICH Q10 names monitoring of process performance and product quality, CAPA, change control and management review as central components of a pharmaceutical quality system.
ICH Q9 requires assessing quality risks scientifically and adapting the intensity of effort, formality and documentation to the risk. For clinical trials, ICH E6(R3) requires building quality into planning and execution and prospectively managing quality-critical factors. GxP compliance is thus not achieved through mere document volume, but through fit-for-purpose, actually implemented and verifiable processes.
Differentiation from compliance
GxP designates the family of regulations and quality principles. Compliance, on the other hand, describes the state or verifiable practice of adhering to these and other applicable requirements. An organization can be subject to GMP, GCP or GVP requirements; its compliance is judged by whether it effectively fulfills the respectively applicable duties.
The terms are therefore closely linked, but not interchangeable. GxP provides the normative framework, compliance its implementation and adherence. Outside the regulatory context, compliance can also mean treatment adherence. This medical meaning of adherence is to be clearly separated from GxP regulatory compliance.
A medicinal product can touch multiple GxP areas along its lifecycle: Non-clinical safety data are generated under GLP principles, clinical trials under GCP, active substance and drug manufacturing under GMP, transport and storage under GDP and post-marketing safety monitoring under GVP. Handovers between these areas are particularly relevant because data, materials and responsibilities must remain consistent.
A risk-based quality management does not prevent every deviation, but creates structures for early detection, evaluation, correction and prevention. The respective responsible party must maintain appropriate oversight even when delegating to service providers. GxP is thus not a single certificate and not a one-time status, but a cross-organizational framework for continuously controlled activities.
The practical application of GxP requires a clear assignment of activities. Not every organization carries out all areas itself, but their interfaces must be regulated. For example, a clinical trial requires information about the released investigational medicinal product batch and suitable delivery conditions; safety information must reach the responsible processes in a timely manner. Written agreements, qualified personnel, controlled systems and verifiable records make these handovers traceable. If functions are outsourced, selection, qualification and oversight remain central GxP tasks. This creates a coherent quality system instead of a series of separate regulations.
Relevance for clinical trials
Clinical trials lie at the intersection of several GxP areas. GCP shapes protection and trial execution, GMP the manufacturing and release of investigational medicinal products, GDP can affect the supply chain and GVP safety processes. Risks arise particularly where information or responsibilities change between sponsor, manufacturer, depot, trial site and service providers. A coordinated quality management keeps these interfaces auditable.
Full-service CROs such as Mediconomics support the implementation of GCP-related processes, monitoring, data management, pharmacovigilance, document control and the coordination of interfaces to GMP-relevant investigational medicinal product logistics. Together with the sponsor, they can structure roles, training, quality risks and evidence across the trial phases and support the oversight of contracted services.
Frequently Asked Questions (FAQ)
What does the “x” in GxP stand for?
It is a placeholder for the area of application of good practice, for example manufacturing, clinical, laboratory, distribution or pharmacovigilance.
Is GxP the same as compliance?
No. GxP is the family of regulations. Compliance is the adherence to the requirements applicable for an activity.
Does only GCP apply in a clinical trial?
No. Besides GCP, in particular GMP for investigational medicinal products, GDP for the supply chain and GVP-related safety processes can be relevant.
Regulatory references
- EudraLex Volume 4 – contains the EU GMP guidelines for medicinal products and active substances.
- ICH E6(R3) Good Clinical Practice – describes the GCP principles for clinical trials.
- Regulation (EU) No 536/2014 – anchors good clinical practice for clinical trials in the EU.
- ICH Q9 and ICH Q10 – describe quality risk management and the pharmaceutical quality system.